ISSN: 2639-2178
Authors: Ashish A, Shah A, Chaturvedi CP, Yadav AK, Singh R*
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder occurring in the elderly population. Millions of people in the age group of 60 and above are affected by Alzheimer’s disease worldwide. Damage caused by disease is currently irreversible and incurable. Early-onset and diagnosis of AD could help in delaying the progression of the disease. Earlier AD was diagnosed by clinical assessment and postmortem brain pathology. Therefore, improved approaches are required to sensitively track disease development and therapeutic efficacy. The pathological presence of ß amyloid plaques and Tau neurofibrillary tangles in cerebrospinal fluid (CSF) is the hallmark of detection. MicroRNAs (miRNAs), a 19-22 nucleotide noncoding RNAs circulating in the blood, regulates gene expression by protein repression. miRNAs are key regulators of gene expression in various biological processes and is emerging as a novel prognostic biomarker in various diseases. Recent evidence suggests the role of miRNAs in disease progression and pathogenesis of AD. Five databases, PubMed” MEDLINE, EMBASE, Web of Sciences, and Cochrane Library, were searched, using a combination of Mesh database or Emtree headings and free-text terms, to identify literature relating to miRNAs in Alzheimer’s disease. The comprehensive online electronic databases, only peer-reviewed, full-text original research articles including English literature, were included in the current review. The studies followed the inclusion criteria were critically assessed and checked using the PRISMA tool. In this review role of miRNAs as potential biomarkers in AD progression and pathogenesis will be covered with its elaborative function as a novel prognostic biomarker and its future prospects in the clinical implication of the same.
Keywords: Alzheimer’s Disease; Biomarker; MiRNA; MiRNA Profiling; Neurodegenerative Disease
